Objectives: To evaluate dose-response relationship of BGG492 as add-on therapy to 1-3 antiepileptic drugs in patients with partial-onset seizures and to investigate safety and tolerability of BGG492. Methods: This was a 12-week, randomized, double-blind, placebo-controlled, phase II dose-titration study (core study) with a 30-week, flexible-dose, open-label extension. In the core study, patients were randomized (1:2) to placebo or BGG492 100 mg t.i.d. in cohort 1, and in cohort 2 patients were randomized (1:4) to placebo or BGG492 150 mg t.i.d. On completion of the core study, eligible patients entered the extension study. Primary outcome measures were total partial seizure frequency per 28 days (core study) and safety and tolerability (extension study). Results: Overall, 93 patients were randomized (150 mg [n = 44]; 100 mg [n = 24]; placebo [n = 25]), and 81 (87.1%) completed the core study. Fifty-one patients entered and 43 (84.3%) completed the extension study. In the core study, no statistically significant dose-response trend among the BGG492 treatment groups (100 and 150 mg) was observed at the 4-week double-blind maintenance period (weeks 7-10); however, there was higher percent reduction in total partial seizure frequency in the BGG492 150 mg over placebo groups (37.32%; 95% confidence interval [CI] À18.90, 66.95). Dizziness, somnolence, and fatigue were the most common adverse events (AEs), higher in the BGG492 150 mg group than in the 100 mg and placebo groups Significance: There was no significant dose-response trend in the BGG492 treatment groups (100 and 150 mg); however, higher percent reduction over placebo was observed in the BGG492 150 mg group. Safety and tolerability data were consistent with the known safety profile for BGG492, and no new safety risks were identified.
Epilepsy is one of the most common neurologic disorders, characterized by uncontrolled firing of the neurons, and worldwide an estimated 50 million people have epilepsy. 1 Approximately 20-30% patients with epilepsy are, or become, refractory to treatment. 2 Consequently, there is a rationale for continued efforts to improve outcomes through the investigation of antiepileptic drugs (AEDs) with novel mechanisms of action. 3 A role for both excitatory a-amino-3-hydroxyl-5-methyl-4-isoxaolepropioic acid (AMPA) and kainate receptors in the pathophysiology of epilepsy has long been hypothesized. 4, 5 Studies have shown efficacy of a noncompetitive AMPAreceptor antagonist, perampanel, as an adjunctive AED in the treatment of patients with partial-onset seizures. 6 BGG492 (selurampanel) 7 is an orally active, competitive AMPA (subunits GluA1-4)/kainate (ion channels GluK1-2) receptor antagonist. Results from the preclinical studies have shown clear anticonvulsive activity of BGG492 in a wide range of rodent epilepsy models including the following: DBA/2 mouse audiogenic seizure model; maximal electroshock and pentylenetetrazol test in rodents; and WAG/Rij rat model and kindled rat model (BGG492 Investigator's Brochure, Novartis data on file). In addition, BGG492 showed a dose-dependent positive effect on the photoparoxysmal response and standardized photoparoxysmal response in epilepsy patients with a generalized photoparoxysmal electroencephalography (EEG) response. 8 The results from the randomized, double-blind, placebocontrolled, single ascending dose study in healthy male volunteers (n = 117) showed that BGG492 was well tolerated in those receiving single oral doses of 1.5-450 mg (CBGG492A2101, Novartis data on file).
Herein we present the results of a double-blind, placebocontrolled phase II dose-titration study (core study) and its open-label extension. The purpose of these studies was to explore the dose-response relationship of BGG492 100 mg and 150 mg administered orally three times daily (t.i.d.) as add-on therapy to 1-3 AEDs in patients with refractory partial-onset seizures and to assess safety and tolerability.
Methods

Study design
Core study
The core study was a randomized, double-blind, placebocontrolled, phase II dose-titration study of 12 weeks' duration (core study; ClinicalTrials.gov identifier: NCT01147003) conducted between June 2010 and September 2011, at 23 centers across Germany, Hungary, Italy, Poland, Republic of Korea, Slovak Republic, and the United States. The study comprised a 4-to 8-week, pretreatment phase; a 10-week, double-blind treatment evaluation phase; and a 2-week, double-blind dose tapering phase (Fig. 1A ). In the core study, patients were randomized in the 1:2 ratio to receive placebo or BGG492 100 mg t.i.d. in cohort 1; whereas in cohort 2, patients were randomized in the 1:4 ratio to receive placebo or BGG492 150 mg t.i.d. Based on participation of patients in the open-label extension, patients entered the double-blind dose tapering phase and received an additional 1 or 2 weeks of double-bind treatment, respectively.
Extension study
On completion of the 10-week double-blind treatment evaluation phase plus 1-2 weeks of dose tapering in the core study, patients who were considered eligible and provided written informed consent entered the 30-week, flexible-dose, open-label extension study (ClinicalTrials.gov identifier: NCT01338805) and continued receiving BGG492 treatment for a maximum of 29 weeks. The openlabel extension study comprised a 4-week titration period, a 22-week maintenance period, and a 3-week follow-up period (Fig. 1A) . Patients returned to the study center at week 30 (i.e., final visit), one week after the final BGG492 dose, for final assessments.
Conduct of both studies
The study protocol and the amendment were reviewed by the independent ethics committee or institutional review board for each center. Studies were conducted in accordance with the International Conference on Harmonization Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC, US Code of Federal Regulations Title 21), and with the ethical principles of the Declaration of Helsinki.
Written informed consent was obtained from each patient before starting any study-specific procedures.
• No significant dose-response trend was observed among the BGG492 treatment groups in the core study; however, higher percent reduction over placebo was observed with BGG492 150 mg
• The post hoc analysis provided alternative interpretation of the data from the core study, and the findings showed a dose-dependent seizure reduction with BGG492
• Overall, the long-term safety and tolerability data from the extension study were consistent with the known safety profile for BGG492; no new safety risks were identified (cohort 2) after 2 weeks, to the target dose of 100 mg and 150 mg t.i.d. after 6 weeks of treatment in the respective cohorts. Optional back titration: Based on the investigator's clinical judgment an optional single one-step dose reduction was permitted during weeks 3-10 as an alternative to premature patient withdrawal for those not tolerating their target dose at that time. Patients not tolerating the study medication during the first 2 weeks discontinued the study. The maximum duration of treatment with BGG492 (selurampanel) in the core study was 11 weeks: a 2-week titration period, two 4-week maintenance periods, and a 1-week tapering-off period. Analysis set: Randomized set included all patients who received a randomization number. Full-analysis set (FAS) included all patients in the randomized set who received at least one dose of study medication and have at least one postbaseline evaluation on the efficacy end point. Safety analysis set included all patients who received at least one dose of study medication and had at least one postbaseline safety assessment. Per protocol set included all patients in the FAS who completed 4 weeks of BGG492 (100 mg or 150 mg) or placebo treatment during weeks 7-10 without any major protocol deviations. (B) Extension study: Last dose of the double-blind medication (day 78, week 12) may be taken on the same date as the first dose of open-label BGG492 in the extension study (day 1). The maximum duration of treatment with BGG492 was 29 weeks: a 4-week titration period; a 22-week maintenance period; and a 3-week follow-up period. The follow-up period comprised a dose-tapering phase and a follow-up visit conducted one week after the administration of the last dose of the study medication. During the follow-up period, patients on 150 mg t.i.d. had their dose reduced to 100 mg t.i.d. for 1 week and then to 50 mg t.i.d. for 1 week; patients on 100 mg t.i.d. had their dose reduced to 50 mg t.i.d. and maintained at that level for 2 weeks; and patients on 50 mg t.i.d. did not undergo dose tapering and remained on this dose-level for 2 weeks. Patients were asked to return to the study center for the final assessments at week 30, one week after the final dose of BGG492 administration. *Treatment interruption of >3 weeks between visit 9 in double-blind study and visit 1 in open-label extension study. †Patients with treatment gap must undergo a rescreening to confirm eligibility. The all treated extension set was the only data analysis set in the extension study that consisted of all patients who enter the extension study and received at least one dose of the extension study medication. R, randomization. Epilepsia ILAE
Patients
Core study
The core study included male and female patients (aged 18-65 years, inclusive) with a diagnosis of epilepsy with partial seizures (≥2 years prior to screening) with or without secondary generalized seizures according to the International League Against Epilepsy's Classification of Epileptic Seizures. 9 Those patients with uncontrolled partial seizures despite treatment with at least two different AEDs within the last 2 years prior to screening were included. In addition, patients were required to have experienced at least four partial seizures during the 4-week prospective baseline period and 4 weeks immediately preceding the baseline period. Patients with no 28-day seizure-free period during the 8 weeks preceding randomization; and those receiving stable treatment with one or two AEDs in cohort 1 and one or a maximum of three AEDs in cohort 2 were included in the study. The key exclusion criteria in the core study were the presence of only nonmotor simple partial seizures; psychogenic seizures within 52 weeks prior to screening; absences and/or myoclonic seizures (e.g., in the context of primary generalized epilepsy); history of Lennox-Gastaut syndrome; status epilepticus or seizure clusters within 52 weeks prior to randomization; treatment with felbamate, vigabatrin, monoamine oxidase inhibitors, tricyclic antidepressants and narcotic analgesics, barbiturates (except for seizure control), intermittent benzodiazepines two or more times in a 4-week period prior to randomization, and L-dopa formulations.
Extension study
Eligible patients were male and female outpatients aged 18-66 years (inclusive) who had completed the core study, cooperated with the study procedures, and had not experienced persistent tolerability issues. Patients who provided written informed consent to continue BGG492 treatment and whose investigators believed a reasonable benefit from the administration of BGG492 might have been expected were included. Patients were also included if they were being treated with a stable dose of one or a maximum of three licensed AEDs and were known to take their medication(s) as directed. To ensure that the study population was representative of all eligible patients, no additional exclusions were applied by the investigator. The key exclusion criteria were a history of status epilepticus or seizure clusters occurring during the core study and use of another investigational drug (other than BGG492) either at the time of enrollment in this extension study or within five half-lives prior to enrollment in this extension study if the experimental medication was taken during the potential treatment gap between the studies.
Outcome measures
The primary efficacy variable of the core study was to detect dose-response trend among the BGG492 treatment groups (100 mg and 150 mg), as measured by change in seizure frequency from the 4-week baseline period (weeks À4 to À1) to the 4-week double-blind maintenance period (weeks 7-10). The main secondary efficacy variable was to evaluate efficacy of BGG492 (100 mg t.i.d., 150 mg t.i.d.) compared with placebo, as assessed by change in seizure frequency from the 4-week baseline period (weeks À4 to À1) to the 4-week double-blind maintenance period (weeks 7-10). In the extension study, the primary objective was to evaluate the safety and tolerability of BGG492 50 mg, 100 mg, and 150 mg t.i.d. in patients with partial-onset seizures. The secondary end points common to both studies included change in seizure frequency, responder rate (≥50% reduction in seizure frequency per 28 days from baseline), proportion of seizure-free patients, and incidence of adverse events (AEs) as well as serious AEs (SAEs) during the study.
Additional dose-response analysis
The post hoc, model-based, exposure-seizure reduction analysis provided alternative interpretation of the data from the core study. In the core study, a longitudinal Poisson regression model was used to explore the BGG492 dose-seizure reduction relationship, including seizure counts from both titration and maintenance phases, and to draw inferences concerning dose-seizure reduction at different doses by simulating seizure reduction from placebo.
Statistical analysis
A sample size of 65 completed patients (n = 17, 19, and 29 for placebo, BGG492 100 mg, and 150 mg, respectively) from the core study was required to provide at least 80% power to detect a significant dose-response signal at one-sided 0.025 significance level. Assuming an overall dropout rate 20%, about 81 patients were to be randomized. For secondary analysis, a sample size of 17 and 29 for placebo and BGG492 150 mg, respectively, would have at least 67% power to detect a 30% treatment difference versus placebo in terms of natural log-transformed postbaseline and baseline seizure frequency ratio with common standard deviation (SD) of 0.625.
In the core study, all efficacy evaluations were performed on the full-analysis set (FAS), the analysis of the primary efficacy was performed on both the FAS and per-protocol set (PPS), and safety evaluations were on the safety set. The all treated extension set was the only data analysis set that was planned for the extension study. In both studies summary statistics included n, mean, SD, median, minimum, and maximum values for continuous variables, and frequencies and percentages for categorical variables.
The BGG492 dose-response relationship was tested for the primary objective in the core study using the multiple comparison approach (MCP)-MOD methodology. 10 The MCP-MOD was adopted in combination of an analysis of covariance (ANCOVA) model to allow for covariate adjustment. The natural log-transformed seizure frequency per 28 days was used in the ANCOVA model as the response variable. The null hypothesis that the dose-response for BGG492 is flat was tested against the alternative hypothesis that BGG492 dose-response relationship showed an increasing trend with increasing doses. The hypothesis test was based on four candidate models (Fig. S1 ) specified with selected fixed parameters to describe the candidate dose-response shapes. It was assumed that for all four models, the percent reductions in seizure frequency over baseline were 20% and 50% for placebo and 150 mg groups, respectively. Each candidate dose-response shape had an optimal contrast test for dose-response signal associated with it. The tests utilized the least square means (LSMs) from the ANCOVA estimation. All tests were used to facilitate the selection of the most likely model and detection of the dose-response relationship, using a one-sided testing, with an overall type one error of 2.5%, after appropriate adjustment for multiplicity. Models with an adjusted one-sided p < 0.025 were significantly different from constant doseresponse (i.e., no dose response) model. The adjusted p-values were obtained by adjusting for multiple comparisons of the candidate dose-response models with a flat dose-response model. Treatment differences in seizure frequency and in change from baseline in seizure frequency per 28 days during the specified double-blind maintenance period (weeks 7-10) were analyzed using ANCOVA model. Treatment difference in responder rate and proportion of seizure-free patients in the core study was tested using a logistic regression model with treatment, region, and AED type as factors and baseline log seizure frequency as covariate. Odds ratio and its 95% confidence interval (CI) between BGG492 cohorts and placebo were reported together with p-value. Wilcoxon's rank-sum test was used in the core study to compare the percent change from baseline to the 4-week double-blind maintenance period (weeks 7-10) in seizure frequency per 28 days between the BGG492 cohorts and the placebo cohort. In the extension study, all efficacy variables including seizure frequency, percent change in seizure frequency from baseline, responder rate, and number and percentage of patients becoming seizure-free were summarized by visits.
Additional dose-response analysis
A longitudinal Poisson regression model was used to describe the time course of weekly seizure counts from baseline, to titration phase and the maintenance phase, thus also considering signals in the data prior to the final 4-week maintenance phase. The model included a placebo effect and linked weekly seizure count to the actual total weekly dose by a direct effect Emax model. Intersubject variations (random effects) were modeled to the placebo term and the Emax term. The inference concerning dose-seizure reduction at difference doses of BGG492 from placebo was drawn by simulating the clinical efficacy at doses range from 1 mg t.i.d. to 300 mg t.i.d., based on 100 simulated patient samples at each dose. For each patient, a dose-response was generated using the maximal effect on seizure rate by BGG492 on the log-scale (Emax) and the BGG492 dose at which 50% of seizure rate is suppressed (ED 50 ) values drawn from a multivariate Gaussian distribution, where the mean, variance, and covariance were estimated by fitting data from the core study to the longitudinal Poisson regression model. The dose-seizure reduction relationship based on the simulation is shown in Figure 2 .
Results
Of the 93 randomized patients, 81 (87.1%) completed the core study (Fig. 1B) ; a total of 51 patients entered the extension study, and among these patients (n = 51), 24 were without a treatment gap between the core study and the extension and 27 were with treatment gap (Fig. 1B) . Overall, there were 12 patients (12.9%) from the core study and 8 (15.7%) from the extension study who prematurely discontinued the study medication, with AEs being the primary reason for discontinuation (8 [8.6%] and 3 [5.9%] in the respective studies) (Fig. 1B) . In the core study, baseline demographics were similar across treatment groups, and patient characteristics were consistent with the refractory epilepsy patient population ( Table 1 ). The mean (SD) total partial seizure frequency per 28 days at baseline in the core and extension studies were 27.4 (47.81) and 18.8 (23.08), respectively ( Table 1 ). The mean (SD) duration of exposure to the study drug during the double-blind treatment evaluation period was 66.1 (15.65) days (range 2-79 days) in the core study, whereas in the extension study it was 182.4 (43.44) days (range 19-212 days). At baseline (core study), levetiracetam (n = 32; 34.4%), carbamazepine (n = 30; 32.3%), lamotrigine (n = 27; 29%), and valproate (n = 27; 29%) were the most frequently prescribed AEDs.
Efficacy results
Core study
Results of the primary end point analysis showed no statistically significant dose-response among the BGG492 treatment groups, and similar results were observed in the per-protocol analysis. Consequently, the null hypothesis of BGG492 flat dose-response was not rejected because there was no significant MCP result favoring monotonic doseresponse relationship.
The between-treatment analysis of change (LSM) at the end of 4-week double-blind maintenance period (weeks 7-10) from baseline in the total partial seizure frequency over placebo were À0.47 (95% CI À1.11 to 0.17) for the BGG492 150 mg and À0.29 (95% CI À1.02 to 0.44) for the BGG492 100 mg groups, and were not significant (p-value: 0.1051 and 0.3765, respectively). The mean percent reductions in the total partial seizure frequency over placebo were 37.32% and 25.08% in the respective BGG492 treatment groups. The median percent reductions at the end of 4-week double-blind maintenance period (weeks 7-10) from baseline in the total partial seizure frequency were 30% for the BGG492 150 mg group and 33.4% for the BGG492 (Table 2a) . A higher proportion of patients in the BGG492 150 mg treatment had higher percent reductions in seizure frequency. The responder rate during the 4-week double-blind maintenance period (weeks 7-10) was numerically higher in the BGG492 150 mg group (n = 14) than the BGG492 100 mg t.i.d. (n = 5) and placebo groups (n = 4); treatment comparison to placebo based on the logistic regression model showed no statistical significance (Table 2b ). The median percent reductions in the total partial seizure frequency at the end of 10-week double-blind treatment evaluation phase (weeks 1-10) from baseline were 23.5% for BGG492 150 mg group and 19.0% 100 mg group compared to 7.6% in placebo (Table 2c ).
During the 4-week double-blind maintenance period (weeks 7-10), there were numerically higher numbers of seizurefree patients in the BGG492 150 mg group (7.7%) compared to the BGG492 100 mg t.i.d. (4.5%) and placebo groups (4.2%); treatment comparison to placebo based on the logistic regression model showed no statistical significance (Table 2d) . (a) Seizure frequency per 28 days: seizure frequency during a specified period / the number of days the seizure information were provided) 9 28. Percent change in seizure frequency from baseline: 100 9 (seizure frequency per 28 days during the baseline period -seizure frequency per 28 days during a specified double-blind period)/ seizure frequency per 28 days during the baseline period. Positive change indicates a reduction from baseline.
Extension study
(c) Change in seizure frequency from baseline = B-T, B = Seizure frequency per 28 days during baseline period, T = Seizure frequency per 28 days during the 10-week double-blind treatment evaluation phase. Percent change in seizure frequency from baseline = 100 (B-T)/B, B = Seizure frequency per 28 days during baseline period, T = Seizure frequency per 28 days during the 4-week double-blind period. A positive change indicates a reduction from baseline. Seizure frequency per 28 days is calculated as: (seizure frequency during the specified double-blind period / the number of days the seizure information were provided) 9 28. a Only patients with nonzero seizure frequency count at baseline are included in percent change calculation. n is the number of patients with nonmissing seizure information during the specified period. postbaseline 9.3 [8.41] ). The median percent reduction in the total partial seizure frequency per 28 days from the baseline period in the core study to open-label extension study for weeks 1-26 (titration and maintenance periods combined) as well as weeks 5-26 (maintenance period alone) were 45% and 43%, respectively. During the openlabel maintenance phase (weeks 5-26) there were a total of 22 responders (44.0%) of the 50 patients with seizure information. A similar responder rate was observed in the titration period (weeks 1-4; 23 responders of 51 patients with seizure information, 45.1%), whereas the responder rate was slightly lower in the dose tapering and follow-up period (weeks 27-30; 18 responders of 47 patients with seizure information, 38.3%). During the open-label maintenance period (weeks 5-26), one (2.0%) of the 50 patients with seizure information was seizure-free.
Safety
Core study
A total of 61 patients (65.6%) experienced AEs during the 10-week, double-blind treatment evaluation period ( Table 3 ). The most common AEs were dizziness, somnolence, and fatigue, and the incidence of these AEs was higher in the BGG492 150 mg group than the BGG492 100 mg and placebo groups (Table 3) . Overall, nervous system disorders (n = 31, 33.3%), general disorders and administration site conditions (n = 15, 16.1%), and gastrointestinal disorders (n = 14; 15.1%) were the most commonly affected primary system organ class (≥10% of patients) during the 10-week double-blind treatment evaluation period. In all treatment groups, most of the AEs were mild or moderate in severity. Of the 61 patients with AEs, five reported AEs (n = 7) of severe intensity including dizziness (n = 2), diplopia (n = 1), gait disturbance (n = 1) in the BGG492 150 mg group; headache (n = 1) and urinary tract infection (n = 1) in the BGG492 100 mg group; and insomnia (n = 1) in the placebo group. Of 12 patients who discontinued (i.e., 12 of 93 randomized patients), 8 discontinuations during the 10-week double-blind treatment evaluation phase were due to AEs: 6 patients in BGG492 150 mg group and 2 in BGG492 100 mg group. Of the 93 patients in the safety analysis set, 6 (6.5%) had experienced one or more SAEs during the 10-week double-blind treatment evaluation period: three patients each in the BGG492 150 mg t.i.d. and 100 mg groups. The SAEs related to the nervous system disorder were higher in both BGG492 150 mg and 100 mg groups. No deaths were reported during the core study.
Extension study
A total of 39 patients (76.5%) experienced AEs during the open-label extension study (weeks 1-30). All AEs were mild-to-moderate in severity (Table 3) . Dizziness (n = 14, 27.5%) and somnolence (n = 9, 17.6%) were the most commonly experienced AEs (Table 3) . Nervous system disorders (n = 24, 47.1%) and general disorders and administration site conditions (n = 8, 15.7%) were the most commonly affected primary system organ class (≥10% of patients). The discontinuations due to AEs were reported from three patients (5.9%) inclusive of the patient who experienced SAEs. The AEs leading to the study drug discontinuation by preferred term were fatigue, headache, dependence, and depression. Only one patient (2.0%) reported four SAEs, and two of these SAEs (dependence and depression) also resulted in the study drug discontinuation. No deaths were reported during the study.
Additional analysis
In the model-based post hoc analysis, BGG492 appeared efficacious in epilepsy with a maximal efficacy of 33% seizure reduction over placebo; the 50% effective dose ED 50 was 17 mg t.i.d., with 95% CI (5.55 to 54.05 mg). Accordingly, 150 mg t.i.d. was predicted to be approximately ED90, and reduced seizure count over placebo by 31% with 90% CI (18% to 41%). The percentages of seizure reduction from placebo by BGG492 doses of 20 mg, 50 mg, 100 mg, and 150 mg t.i.d. are also shown in the table in Figure 2 . The incremental seizure reduction was small beyond the BGG492 dose of 150 mg t.i.d..
Discussion
The pharmacologic studies have shown BGG492 to be an orally active, competitive AMPA/kainate receptor antagonist, and the preclinical and clinical evidence has suggested the potential of BGG492 in the management of epilepsy. In this proof-of-concept study (i.e., core study), no statistically significant dose-response trend was observed in the BGG492 treatment groups (100 mg and 150 mg). The dose-response relationship appeared to be relatively flat in the BGG492 treatment groups (100 mg and 150 mg), and one potential explanation could be the observed difference in disease characteristics between the BGG492 100 mg and 150 mg groups. The BGG492 150 mg t.i.d. group had more AEDs since diagnosis of partial epilepsy, more concomitant AEDs at baseline, more patients with a history of epilepsy surgery at baseline, and a slightly higher baseline seizure frequency compared with the BGG492 100 mg t.i.d. group. The patient population in this proof-of-concept study was extremely selective, comparable to the phase III randomized studies of perampanel. 6 Even the tendency toward improvement is a clear argument for the anticonvulsive potency of the drug. A numerical difference in change in the total partial seizure frequency per 28 days from baseline compared to placebo was observed in both BGG492 150 mg and 100 mg groups in the core study. The study was not powered to detect a statistical significant outcome for this evaluation. In the extension study, the change and percent change in the partial seizure frequency per 28 days from the original baseline period was in range of that observed in the core study.
The primary analysis of the core study failed to demonstrate dose-response for BGG492 for refractory epilepsy. A post hoc model-based exposure-seizure reduction analysis was therefore performed to provide alternative interpretation of the data from the core study. For the model, the lower doses and treatment periods outside weeks 7-10 were included. Results from the model-based longitudinal analysis of the totality of the data from the core study demonstrated a statistically significant treatment effect; and that the reduction of weekly seizure risk by BGG492 depends on the actual total BGG492 dose taken in the corresponding week. This analysis was considered more sensitive for the following reasons. First, it has been established in the literature 11, 12 that seizure count was better described by a Poisson distribution or a negative binomial distribution (long-tailed Poisson distribution), and therefore this model-based approach is "exact" in the statistical sense, taking advantage of the nature of count data. Second, the primary analysis ignored the titration and noncompliance during the study, thereby diluting treatment signal and making it difficult for establishing a dose-response relationship; conversely, the model-based analysis used actual dose while assessing dose-seizure reduction relationship. The dose changes due to titration and compliance therefore helped characterizing the dose-seizure reduction relationship. Third, in the primary analysis, the missing values were imputed using the last observation carried forward (LOCF) approach while a patient dropped out of the study in the titration phase but did not reach the full efficacy potential, thereby diluting the efficacy signal; conversely, the model-based approach took data "as-is," thereby avoiding potential bias induced by LOCF. Finally, the model-based longitudinal analysis used all data instead of a snap-shot of the data as in the primary analysis, thereby contributing to the increased sensitivity to pick up a moderate but persistent signal that might be missed by an end point-type of analysis.
In addition, the results of responder analysis corroborated the observations related to change in the partial seizure frequency. Because flexible dosing was followed in the extension study, no correlation between specific doses and efficacy results were evaluated. In the present studies, the most commonly reported AEs for BGG492 were similar to those reported previously in the BGG492A studies, and were consistent with that reported for other AEDs (perampanel). 13 The analysis in the present studies did not allow for evaluation of the exact incidence of AEs observed under a specific dose because of the dose-titration design. The core study supports the preliminary evidence of efficacy of BGG492 as add-on therapy to other concomitant AEDs in epilepsy population with refractory partial-onset seizures.
In conclusion, no significant dose-response trend was observed among the BGG492 treatment groups; however, higher percent reduction over placebo was observed in BGG492 150 mg. No new safety risks were identified in this extension study. A model-based analysis, however, indicated a dose-dependent seizure reduction with BGG492.
